VNDA Stock Forecast: Vanda Pharmaceuticals, Inc. Price Predictions for 2026-2027
The median 12-month analyst price target for Vanda Pharmaceuticals, Inc. is $11. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 72 of 100 as at 21 Nov 2026 — in the upper half.
One number for the whole business
Consensus tells you what everyone already believes. The model scores Vanda Pharmaceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Accruals (91): Reported profit is backed by cash, and the company is not expanding recklessly.
Issuance (30): The company has been issuing shares or taking on financing, diluting existing holders.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
VNDA stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on VNDA, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
Of the 20 most recent actions, 0 moved their price target up and 3 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 5 Oct 2026 | HC Wainwright & Co. | Reiterates | Buy | $20 |
| 23 Sept 2026 | Oppenheimer | Initiates | Outperform | $10 |
| 10 Aug 2026 | B. Riley Securities | Reiterates | Buy | $17 → $12 |
| 10 Aug 2026 | HC Wainwright & Co. | Maintains | Buy | $21 → $20 |
| 11 May 2026 | HC Wainwright & Co. | Maintains | Buy | $24 → $21 |
| 5 Mar 2026 | Truist Securities | Initiates | Buy | — |
| 23 Feb 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 5 Jan 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 31 Dec 2025 | B. Riley Securities | Maintains | Buy | — |
| 31 Dec 2025 | Jefferies | Maintains | Hold | — |
| 19 Nov 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 5 Nov 2025 | B. Riley Securities | Initiates | Buy | — |
| 30 Oct 2025 | Cantor Fitzgerald | Maintains | Overweight | — |
| 21 Aug 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 14 May 2025 | Cantor Fitzgerald | Assumes | Overweight | $13 |
| 7 May 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 1 Apr 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 18 Feb 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 4 Feb 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 28 Jan 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for VNDA.
This page is one stock. Monday covers all of them.
VNDA appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
VNDA vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 20 Nov 2026, Vanda Pharmaceuticals, Inc. returned −28.9% against +6.9% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
VNDA analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- 0.9×
- Price / book
- 1.0×
- EV / EBITDA
- —
Cheaper than 68% of US stocks
Cheaper than 69% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- 93.0%
- Operating margin
- −77.6%
- Net margin
- —
Higher than 97% of US stocks
Higher than 16% of US stocks
- Return on equity
- −82.5%
- Return on assets
- −22.6%
- Dividend yield
- —
Higher than 16% of US stocks
Higher than 18% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Vanda Pharmaceuticals, Inc. has a market value of $208.6M and an enterprise value of $89.8M.
Revenue in the twelve months to 30 June 2026: $215.7M. The latest quarter shrank 3.9% year on year.
Net income over the same four quarters: −$274.9M, a −127.4% net margin.
Diluted earnings per share, trailing twelve months: −$4.63.
Free cash flow in the twelve months to 30 June 2026: −$153.0M.
forward P/E: 17.2× — the forward figure prices analyst consensus estimates, not reported earnings.
Vanda Pharmaceuticals, Inc. employs 533 people — $405K of revenue per employee.
Data provided by Twelve Data
VNDA and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at VNDA’s peer groups, ranked by the model: healthcare stocks · biotech stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own Vanda Pharmaceuticals, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about VNDA
What is the VNDA stock price forecast for 2026-2027?
The median 12-month analyst price target for Vanda Pharmaceuticals, Inc. is $11, with estimates ranging from $4.5 to $20. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is VNDA stock a buy right now?
Of the 5 analysts covering Vanda Pharmaceuticals, Inc., 4 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Vanda Pharmaceuticals, Inc. 72 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank VNDA?
As at 21 Nov 2026, Vanda Pharmaceuticals, Inc. ranks 72 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Accruals (91 of 100).
Will VNDA stock go up?
No one can know that. What the data says: the median 12-month target from 5 analysts is $11, and Ticker Nerd's factor model ranks Vanda Pharmaceuticals, Inc. 72 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the VNDA stock forecast for 2030?
No analyst covering Vanda Pharmaceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for VNDA are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $4.5 to $20 over the next 12 months.
How has VNDA stock performed over the past year?
Vanda Pharmaceuticals, Inc. returned -28.9% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Vanda Pharmaceuticals, Inc. do?
Vanda Pharmaceuticals Inc. is a global biopharmaceutical company focused on developing and commercializing therapies for high unmet medical needs. Its current portfolio centers on treatments for sleep-wake disorders, schizophrenia, and other central nervous system conditions, supported by a selective pipeline that includes additional clinical and preclinical programs.
About Vanda Pharmaceuticals, Inc.
Vanda Pharmaceuticals Inc. is a global biopharmaceutical company focused on developing and commercializing therapies for high unmet medical needs. Its current portfolio centers on treatments for sleep-wake disorders, schizophrenia, and other central nervous system conditions, supported by a selective pipeline that includes additional clinical and preclinical programs. The company’s marketed products include HETLIOZ and Fanapt, while PONVORY adds a presence in immune-related therapeutics. Vanda also works on specialty medicines for rare diseases and other targeted indications, using genetics and genomics to guide drug discovery and clinical development. With a concentrated product mix and a research-driven model, Vanda Pharmaceuticals Inc. plays a specialized role in the biopharmaceutical market by addressing niche patient populations where treatment options may be limited.
CEO Dr. Mihael H. Polymeropoulos M.D. · 533 employees · United States · https://www.vandapharma.com